Bharat Parenterals Subsidiary Undergoes U.S. FDA Inspection; Five Observations Issued
Bharat Parenterals Limited's subsidiary, Innoxel Lifesciences Private Limited, recently underwent a surprise and unannounced inspection by the United States Food and Drug Administration (U.S. FDA) at its finished dosage manufacturing facility in Vadodara, Gujarat.The inspection focused on the General Injectables Block and took place across multiple dates: April 13, 2026 to April 17, 2026, and April 20, 2026.
Following the conclusion of the review, the U.S. FDA issued five (5) observations, classifying them under a Voluntary Action Indicated (VAI) category. The company's subsidiary has committed to submitting its formal response within the prescribed timelines, and the final Establishment Inspection Report (EIR) is currently awaited.
The General Injectables Block is highlighted as a critical manufacturing facility responsible for supplying sterile injectable formulations to regulated international markets, including the United States and the European Union.
Facility Regulatory Track Record
The operational history of the facility shows the following regulatory milestones:| Inspection Body | Dates | Observations/Outcome | Details |
|---|---|---|---|
| U.S. FDA | April-May 2025 | EIR received | July 30, 2025 |
| EU GMP (FAMHP) | November 24-28, 2025 | Zero critical and zero major observations | EUGMP Certificate issued March 06, 2026 |
| U.S. FDA | April 13-17, 20, 2026 | Five observations under VAI classification | N/A |
Commentary on the development noted that the outcome, involving procedural observations under a VAI classification, reflects the sustained quality and compliance systems at Innoxel. The company stated that it continues to focus on strengthening its overall manufacturing and regulatory capabilities.
Bharat Parenterals Limited is a BSE-listed pharmaceutical manufacturer with over three decades of formulation expertise, exporting to more than 40 countries. The Group operates through its subsidiaries, Innoxel Lifesciences Private Limited (focused on complex dosage forms and U.S. FDA and EU markets) and Varenyam Healthcare (handling domestic branded generics).
Stock Price Movement
As of 14:00, Bharat Parenterals Ltd shares are edging higher, climbing to ₹1205.00, which represents a 1.63% gain today. Throughout the session, the stock fluctuated between an intraday low of ₹1185.30 and a high of ₹1248.00.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.